Investors Take Action Amid Soleno Therapeutics Securities Fraud Claims and Drug Launch Concerns
In a recent alert, leading national shareholder rights law firm Hagens Berman is urging investors who suffered losses from Soleno Therapeutics, Inc. (NASDAQ: SLNO) to take action amid claims of securities fraud linked to its Prader-Willi syndrome treatment, VYKAT™ XR (DCCR). This follows significant disruptions in the drug’s launch and troubling allegations about the company's misrepresentation of its safety and efficacy. Key deadlines are approaching, particularly the May 5, 2026, cut-off to become a lead plaintiff in a potential class action lawsuit.
The class action revolves around the purported failure of Soleno Therapeutics to honestly disclose critical safety risks associated with DCCR. Allegations point to substantial concerns regarding the drug’s safety, including reports of significant adverse reactions such as fluid retention and potential heart complications in pediatric patients. Throughout the class period, which spans from March 26, 2025, to November 4, 2025, investors were reassured by Soleno that the drug was both effective and safe, claims that are now under scrutiny following public criticism.
A troubling report from activist short-seller Scorpion Capital alleges that Soleno's Phase 3 clinical trial data was not only questionable but also potentially compromised. Their investigation indicates that the analyses were rooted in data from a physician in Gainesville, Florida, known for presenting results that showed signs of irregularities—a red flag about the integrity of the findings. Furthermore, the firm asserts that the metrics being provided by Soleno regarding the commercial launch of DCCR were potentially inflated, artificially enhanced by dubious practices rather than true market demand.
Soleno's troubling path first emerged in August 2025 when Scorpion Capital released its report, entitled 'Russian Roulette With Prader-Willi Children,' thereby catalyzing a notable drop in Soleno's stock price. The report triggered immediate public discourse about the safety profile of DCCR, leading to a double-digit decline in the stock price almost instantly.
Then, on November 4, 2025, the situation intensified when Soleno admitted during its quarterly earnings call that the product launch had not progressed as anticipated. This abrupt acknowledgment of fewer patient enrollments and a higher rate of discontinuations resulted in a staggering 27% drop in the stock within a single trading session. Investor confidence shattered as reality set in, revealing that the assurances provided by Soleno had potentially put hundreds of investors at financial risk.
As the upcoming deadline of May 5, 2026, looms, affected shareholders are being encouraged to document their losses and assess their options regarding participation in the potential class action. Those who purchased stock during the defined Class Period are advised to act promptly to join the lawsuit to hold Soleno accountable for its alleged wrongdoing.
Additionally, whistleblowers who may possess non-public details related to Soleno's actions are being encouraged to come forward with such information, possibly taking part in the SEC's Whistleblower program, which offers substantial financial incentives for original information leading to successful recoveries.
Hagens Berman has established itself as a formidable force in litigation against corporate malpractice and has achieved over $2.9 billion in recoveries for its clients. The law firm continues to push for greater corporate accountability, emphasizing the need for transparency in communications regarding product safety and performance. Investors interested in further information regarding their rights, or how to proceed with legal action, are advised to reach out to Hagens Berman’s dedicated legal team for guidance.
In conclusion, as Soleno Therapeutics continues to face increasing scrutiny and alleged safety risks associated with its flagship product, it remains crucial for potentially affected investors to empower themselves by understanding their legal standing and available recourse options. This case not only highlights the risk of investing in the pharmaceutical industry amid such alarming revelations but also sheds light on the importance of genuine transparency from companies regarding the safety and effectiveness of their products.
The class action revolves around the purported failure of Soleno Therapeutics to honestly disclose critical safety risks associated with DCCR. Allegations point to substantial concerns regarding the drug’s safety, including reports of significant adverse reactions such as fluid retention and potential heart complications in pediatric patients. Throughout the class period, which spans from March 26, 2025, to November 4, 2025, investors were reassured by Soleno that the drug was both effective and safe, claims that are now under scrutiny following public criticism.
A troubling report from activist short-seller Scorpion Capital alleges that Soleno's Phase 3 clinical trial data was not only questionable but also potentially compromised. Their investigation indicates that the analyses were rooted in data from a physician in Gainesville, Florida, known for presenting results that showed signs of irregularities—a red flag about the integrity of the findings. Furthermore, the firm asserts that the metrics being provided by Soleno regarding the commercial launch of DCCR were potentially inflated, artificially enhanced by dubious practices rather than true market demand.
Soleno's troubling path first emerged in August 2025 when Scorpion Capital released its report, entitled 'Russian Roulette With Prader-Willi Children,' thereby catalyzing a notable drop in Soleno's stock price. The report triggered immediate public discourse about the safety profile of DCCR, leading to a double-digit decline in the stock price almost instantly.
Then, on November 4, 2025, the situation intensified when Soleno admitted during its quarterly earnings call that the product launch had not progressed as anticipated. This abrupt acknowledgment of fewer patient enrollments and a higher rate of discontinuations resulted in a staggering 27% drop in the stock within a single trading session. Investor confidence shattered as reality set in, revealing that the assurances provided by Soleno had potentially put hundreds of investors at financial risk.
As the upcoming deadline of May 5, 2026, looms, affected shareholders are being encouraged to document their losses and assess their options regarding participation in the potential class action. Those who purchased stock during the defined Class Period are advised to act promptly to join the lawsuit to hold Soleno accountable for its alleged wrongdoing.
Additionally, whistleblowers who may possess non-public details related to Soleno's actions are being encouraged to come forward with such information, possibly taking part in the SEC's Whistleblower program, which offers substantial financial incentives for original information leading to successful recoveries.
Hagens Berman has established itself as a formidable force in litigation against corporate malpractice and has achieved over $2.9 billion in recoveries for its clients. The law firm continues to push for greater corporate accountability, emphasizing the need for transparency in communications regarding product safety and performance. Investors interested in further information regarding their rights, or how to proceed with legal action, are advised to reach out to Hagens Berman’s dedicated legal team for guidance.
In conclusion, as Soleno Therapeutics continues to face increasing scrutiny and alleged safety risks associated with its flagship product, it remains crucial for potentially affected investors to empower themselves by understanding their legal standing and available recourse options. This case not only highlights the risk of investing in the pharmaceutical industry amid such alarming revelations but also sheds light on the importance of genuine transparency from companies regarding the safety and effectiveness of their products.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.